Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025
Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company specializing in rare genetic skin disease treatments, has scheduled its full year 2024 financial results announcement for March 31, 2025. The company will host a conference call with investors at 8:30 a.m. ET on the same day to discuss financial performance and provide a corporate update.
The presentation will include both a live webcast with slides and a dial-in option for participants. A replay of the webcast will be made available approximately 2 hours after the call concludes and will remain accessible for 90 days through the company's website.
Palvella Therapeutics (Nasdaq: PVLA), un'azienda biofarmaceutica in fase clinica specializzata nel trattamento di malattie genetiche rare della pelle, ha programmato l'annuncio dei risultati finanziari per l'intero anno 2024 per il 31 marzo 2025. L'azienda ospiterà una conference call con gli investitori alle 8:30 a.m. ET dello stesso giorno per discutere le performance finanziarie e fornire un aggiornamento aziendale.
La presentazione includerà sia un webcast dal vivo con diapositive sia un'opzione di partecipazione telefonica. Una registrazione del webcast sarà disponibile circa 2 ore dopo la conclusione della chiamata e rimarrà accessibile per 90 giorni tramite il sito web dell'azienda.
Palvella Therapeutics (Nasdaq: PVLA), una empresa biofarmacéutica en etapa clínica especializada en tratamientos para enfermedades genéticas raras de la piel, ha programado el anuncio de sus resultados financieros para el año completo 2024 para el 31 de marzo de 2025. La empresa llevará a cabo una conferencia telefónica con inversores a las 8:30 a.m. ET el mismo día para discutir el rendimiento financiero y proporcionar una actualización corporativa.
La presentación incluirá tanto una transmisión en vivo con diapositivas como una opción de llamada para los participantes. Una repetición de la transmisión estará disponible aproximadamente 2 horas después de que finalice la llamada y permanecerá accesible durante 90 días a través del sitio web de la empresa.
Palvella Therapeutics (Nasdaq: PVLA), 희귀 유전 피부 질환 치료를 전문으로 하는 임상 단계의 생명공학 회사가 2025년 3월 31일에 2024년 전체 재무 결과 발표를 예정하고 있습니다. 회사는 같은 날 오전 8시 30분 ET에 투자자와의 컨퍼런스 콜을 개최하여 재무 성과를 논의하고 기업 업데이트를 제공할 예정입니다.
프레젠테이션에는 슬라이드가 포함된 라이브 웹캐스트와 참가자를 위한 전화 참여 옵션이 포함됩니다. 웹캐스트의 재생은 통화가 종료된 후 약 2시간 후에 제공되며, 회사 웹사이트를 통해 90일 동안 접근할 수 있습니다.
Palvella Therapeutics (Nasdaq: PVLA), une entreprise biopharmaceutique en phase clinique spécialisée dans les traitements des maladies cutanées génétiques rares, a prévu l'annonce de ses résultats financiers pour l'année complète 2024 pour le 31 mars 2025. L'entreprise organisera une conférence téléphonique avec les investisseurs à 8h30 ET le même jour pour discuter de la performance financière et fournir une mise à jour de l'entreprise.
La présentation comprendra à la fois un webinaire en direct avec des diapositives et une option de participation par téléphone pour les participants. Un enregistrement du webinaire sera disponible environ 2 heures après la fin de l'appel et restera accessible pendant 90 jours via le site web de l'entreprise.
Palvella Therapeutics (Nasdaq: PVLA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Behandlung seltener genetischer Hautkrankheiten spezialisiert hat, hat die Bekanntgabe seiner finanziellen Ergebnisse für das gesamte Jahr 2024 auf den 31. März 2025 terminiert. Das Unternehmen wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz mit Investoren abhalten, um die finanzielle Leistung zu besprechen und ein Unternehmensupdate zu geben.
Die Präsentation wird sowohl ein Live-Webcast mit Folien als auch eine Einwahlnummer für Teilnehmer umfassen. Eine Wiederholung des Webcasts wird etwa 2 Stunden nach Abschluss des Anrufs verfügbar sein und bleibt für 90 Tage über die Unternehmenswebsite zugänglich.
- None.
- None.
WAYNE, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that it will report its full year 2024 financial results on Monday, March 31, 2025.
Palvella management will host a conference call for investors at 8:30 a.m. ET on Monday, March 31, 2025, to discuss financial results and provide a corporate update.
To access the live webcast of the call with slides, please click here or visit the "Events & Presentations" section of Palvella’s website. To access the call by phone, please use this registration link, and you will be provided with dial in details. A replay of the webcast will be available approximately 2 hours after the conclusion of the call and archived for 90 days under the "Events & Presentations" section of the Company's website at www.palvellatx.com.
About Palvella Therapeutics
Founded and led by rare drug disease drug development veterans, Palvella Therapeutics (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN
QTORIN™ rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency.
Contact Information
Investors
Wesley H. Kaupinen
Founder and CEO, Palvella Therapeutics
wes.kaupinen@palvellatx.com
Media
Marcy Nanus
Managing Partner, Trilon Advisors, LLC
mnanus@trilonadvisors.com
FAQ
When will Palvella Therapeutics (PVLA) release its 2024 annual financial results?
What time is Palvella Therapeutics' (PVLA) 2024 earnings call scheduled for?
How long will Palvella Therapeutics' (PVLA) earnings call replay be available?
What is Palvella Therapeutics' (PVLA) primary business focus?
